Other Events ·
Immatics reports IMA402 cORR of 32% in PRAME-high melanoma and durable activity for anzu-cel
IMTXImmatics N.V.
Immatics N.V. announced updated clinical trial data from its Phase 1b study with IMA402, a PRAME-targeted TCR bispecific, showing a confirmed objective response rate (cORR) of 32% in heavily pretreated patients with high PRAME expression across solid tumors, including melanoma and ovarian cancer. The company also presented exploratory analyses for anzu-cel (IMA203), its PRAME-directed cell therapy, demonstrating durable clinical benefit in advanced melanoma. Immatics operates as a clinical-stage biotechnology company focused on precision targeting of the PRAME antigen using TCR-based therapies.